Quick Answer
Aprea Therapeutics, Inc. reported Research And Development Expense of $23.90 million for the year ending 2021.
- Aprea Therapeutics, Inc. showed a decrease of -36.9% in Research And Development Expense from 2020 to 2021.
- This data is from Aprea Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 15, 2022.
- XBRL data for this metric is available from 2017 to 2021 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $2.31 million | Q1 2019: $3.68 million | Q2 2019: $4.32 million | Q3 2019: $4.91 million | Q1 2020: $9.10 million | Q2 2020: $10.69 million | Q3 2020: $8.76 million | Q1 2021: $6.76 million | Q2 2021: $6.65 million | Q3 2021: $6.02 million | Q1 2022: $4.09 million.
- Over the full 5 years of available data (2017 to 2021), Aprea Therapeutics, Inc.'s Research And Development Expense has grown by 78.4%.
- Historical annual values: Fiscal year 2021: $23.90 million | Fiscal year 2020: $37.88 million | Fiscal year 2019: $20.95 million | Fiscal year 2018: $14.19 million | Fiscal year 2017: $13.39 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: